Healthcare provider profile · identity verified

Luis Enrique Torres

Allopathic & Osteopathic Physicians|General Practice · PONCE, PR · NPI 1346216942

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Luis Enrique Torres received $43.16 in general payments during 2025 across 1 reported records.

GENZYME CORPORATION accounted for 100.0% of that reported general-payment amount.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$43.16

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
GENZYME CORPORATION	Unresolved — no canonical attribution shown	$43.16	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$43.16	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Pantoprazole Sodium	Pantoprazole Sodium	733	124
Atorvastatin Calcium	Atorvastatin Calcium	667	223
Gabapentin	Gabapentin	646	104
Famotidine	Famotidine	601	101
Synthroid	Levothyroxine Sodium	413	65
Tamsulosin Hcl	Tamsulosin Hcl	357	71
Lisinopril	Lisinopril	341	103
Omeprazole	Omeprazole	321	58
Losartan Potassium	Losartan Potassium	317	105
Montelukast Sodium	Montelukast Sodium	315	48
Metformin Hcl	Metformin Hcl	301	96
Amlodipine Besylate	Amlodipine Besylate	299	94
Alendronate Sodium	Alendronate Sodium	281	55
Levothyroxine Sodium	Levothyroxine Sodium	270	51
Clonazepam	Clonazepam	236	43
Furosemide	Furosemide	196	45
Hydrochlorothiazide	Hydrochlorothiazide	194	50
Metoprolol Succinate	Metoprolol Succinate	191	62
Clopidogrel	Clopidogrel Bisulfate	183	38
Allopurinol	Allopurinol	180	27
Simvastatin	Simvastatin	177	57
Sulindac	Sulindac	174	42
Nabumetone	Nabumetone	165	44
Glipizide	Glipizide	151	43
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	138	19
Sertraline Hcl	Sertraline Hcl	136	26
Fenofibrate	Fenofibrate	135	30
Rosuvastatin Calcium	Rosuvastatin Calcium	130	47
Jentadueto	Linagliptin/Metformin Hcl	125	41
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	123	44
Cilostazol	Cilostazol	121	21
Fluticasone Propionate	Fluticasone Propionate	120	26
Lantus	Insulin Glargine,hum.Rec.Anlog	114	21
Latanoprost	Latanoprost	113	18
Donepezil Hcl	Donepezil Hcl	99	17
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	97	26
Carvedilol	Carvedilol	93	32
Insulin Syringe	Syringe And Needle,insulin,1ml	91	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	91	30
Finasteride	Finasteride	90	15
Eliquis	Apixaban	84	16
Farxiga	Dapagliflozin Propanediol	84	23
Metoprolol Tartrate	Metoprolol Tartrate	84	29
Albuterol Sulfate Hfa	Albuterol Sulfate	64	16
Betamethasone Valerate	Betamethasone Valerate	64	29
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	64	12
Indapamide	Indapamide	61	12
Baclofen	Baclofen	59	16
Nitroglycerin	Nitroglycerin	59	14
Hydralazine Hcl	Hydralazine Hcl	58	15
Memantine Hcl	Memantine Hcl	56	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	53	suppressed
Alprazolam	Alprazolam	52	13
Jardiance	Empagliflozin	50	15
Gemfibrozil	Gemfibrozil	49	15
Ibuprofen	Ibuprofen	48	19
Meclizine Hcl	Meclizine Hcl	46	14
Citalopram Hbr	Citalopram Hydrobromide	45	suppressed
Lansoprazole	Lansoprazole	45	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	44	13
Levetiracetam	Levetiracetam	43	suppressed
Nifedipine Er	Nifedipine	43	12
Meloxicam	Meloxicam	40	suppressed
Calcitriol	Calcitriol	39	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	39	suppressed
Breo Ellipta	Fluticasone/Vilanterol	37	suppressed
Irbesartan	Irbesartan	36	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	11
Ezetimibe	Ezetimibe	35	16
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	35	suppressed
Pregabalin	Pregabalin	35	suppressed
Temazepam	Temazepam	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Clonidine Hcl	Clonidine Hcl	33	suppressed
Cabergoline	Cabergoline	31	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	31	suppressed
Lorazepam	Lorazepam	31	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	30	suppressed
Glimepiride	Glimepiride	29	12
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Chlorthalidone	Chlorthalidone	28	suppressed
Propranolol Hcl	Propranolol Hcl	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Anastrozole	Anastrozole	26	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Sure Comfort	Syringe And Needle,insulin,1ml	25	suppressed
Etodolac	Etodolac	23	suppressed
Risperidone	Risperidone	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Atenolol	Atenolol	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Naproxen	Naproxen	22	suppressed
Azithromycin	Azithromycin	21	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Cholestyramine Light	Cholestyramine	20	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	20	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	20	suppressed
Lumigan	Bimatoprost	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	18	suppressed
Ranolazine Er	Ranolazine	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Topiramate	Topiramate	17	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Humalog	Insulin Lispro	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Trazodone Hcl	Trazodone Hcl	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Aliskiren	Aliskiren Hemifumarate	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Flecainide Acetate	Flecainide Acetate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Bethanechol Chloride	Bethanechol Chloride	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	12	suppressed
Timolol Maleate	Timolol Maleate	12	suppressed
Atrovent Hfa	Ipratropium Bromide	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Galantamine Er	Galantamine Hbr	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Lactulose	Lactulose	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Novofine 32	Pen Needle, Diabetic	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Synjardy	Empagliflozin/Metformin Hcl	11	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$43.16 · 1 records	GENZYME CORPORATION	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error